Post by
thesheet on Nov 01, 2017 11:30am
Latest run up...
I figure the latest run up has to do with money coming back in ahead of the next results. I’ll hold until they come out probably the next few months....
thesheet
Comment by
Baylor1965 on Nov 01, 2017 12:40pm
No, It’s about the ASH release. https://ash.confex.com/ash/2017/webprogram/Paper100952.html
Comment by
thesheet on Nov 01, 2017 2:42pm
What date did this report come out? Is the timing correlated with the current run Up? I read some old (but good) news and a date for a presentation a month from now. Is this new news? look at the charts where there was a big run up to a to the slightly disappointing results then a crash that followed. Hopefully good news will come at which point I will probably sell. thesheet
Comment by
Baylor1965 on Nov 01, 2017 2:57pm
this morning and it is huge. Game changer for the company and for cancer therapies. Look out for a take over
Comment by
Njdevilsfan on Nov 01, 2017 4:19pm
i'd like to see a partnership. i think they have enough data right now where big pharma would want to make a nice deal with them
Comment by
Baylor1965 on Nov 01, 2017 4:50pm
based in terms of what has happened in the past, what value and what type of partnership would be a fair deal for TRIL?
Comment by
Njdevilsfan on Nov 01, 2017 5:16pm
i really wouldn't know, maybe $50+ million upfront, a few hundred million after successful trials and royalties?
Comment by
Baylor1965 on Nov 02, 2017 7:47pm
I think that’s about right for a single IP. That said, IP is low on the big pharma front and a company like tril, which is an IP bank, could be compensated in a big way for the whole company